Bristol-Myers Squibb Company (NYSE: BMY) stands as a stalwart in the healthcare sector, known for its robust portfolio in the biopharmaceutical landscape. With a market capitalization of $123.7 billion, this American firm has cemented its reputation by developing a broad spectrum of products that cater to oncology, immunology, cardiovascular, and more. As investors evaluate the potential of BMY stock, several financial highlights and performance metrics warrant closer examination.

Currently priced at $60.74, Bristol-Myers Squibb’s stock is nearing the upper end of its 52-week range of $42.60 to $63.11. However, an average target price of $59.91 suggests a slight downside of -1.36%, indicating that the market might have already…